Regeneron Pharmaceuticals (NASDAQ: REGN) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Regeneron was up 4.7% at $813.38. If the gains hold, the stock will notch its highest close since Nov. 12, 2024, when it ...
StockStory.org on MSN
3 reasons to avoid REGN and 1 stock to buy instead
What a fantastic six months it’s been for Regeneron. Shares of the company have skyrocketed 47.6%, hitting $774.98. This was ...
Feb 4 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a ...
The U.S. Department of Justice filed a lawsuit accusing Regeneron Pharmaceuticals of manipulating Medicare pricing by inflating the average sales price for its expensive and widely prescribed Eylea ...
The Department of Justice on Wednesday accused drug maker Regeneron Pharmaceuticals Inc. of fraudulent practices related the pricing of its blockbuster vision-impairment drug Eylea, boosting its sales ...
The Thursday morning update indicates Regeneron Pharmaceuticals shares down by 0.27%, currently priced at $771.87. At this value, Sing's 9,212 shares are worth $2,320,134.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback